{
    "clinical_study": {
        "@rank": "41905", 
        "acronym": "PARAPLY-1", 
        "arm_group": {
            "arm_group_label": "SIB Dose-Escalation radiotherapy", 
            "arm_group_type": "Experimental", 
            "description": "Simultaneous integrated boost to intraprostatatic tumor and lymph nodes"
        }, 
        "brief_summary": {
            "textblock": "A single arm phase 2 study to study the outcome of dose-escalation with simultaneous\n      integrated boost to intraprostatic lesion and positive lymph nodes. Prostate cancer patients\n      with high risk of lymph node metastasis or oligo positive nodes in true pelvic area can be\n      included. The boost volumes will be outlined by usin PET-CT and MRI data. Our hypothesis is\n      that we will have fewer relapses in this very high risk patient group compared to matched\n      historical controls with acceptable side effects."
        }, 
        "brief_title": "Dose Escalation With SIB to Intraprostatic/Lymphatic GTV in High Risk Prostate Cancer", 
        "completion_date": {
            "#text": "November 2020", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Prostatic Neoplasms", 
            "Lymphatic Metastasis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Neoplasms", 
                "Lymphatic Metastasis", 
                "Neoplasm Metastasis", 
                "Prostatic Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed high risk prostate cancer with a risk of lymphatic spread\n             >15% according to the MSKCC nomogram (1)\n             http://nomograms.mskcc.org/Prostate/PreTreatment.aspx\n\n          -  Written informed consent\n\n          -  > 18 years\n\n          -  Fiducial gold markers implanted in the prostate (min 3)\n\n        Exclusion Criteria:\n\n          -  \u2022 Non MR-safe implants or other contraindication to MRI\n\n               -  WHO PS>1\n\n               -  Previous pelvic irradiation\n\n               -  TURP within 6 months\n\n               -  IPSS >19\n\n               -  Metastatic disease in skeleton, parenchymal organs or lymph nodes outside the\n                  pelvis\n\n               -  Creatinin clearance < 30ml/min according to\n                  http://www.fass.se/LIF/produktfakta/kreatinin.jsp"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "86", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01962324", 
            "org_study_id": "PARAPLY-1"
        }, 
        "intervention": {
            "arm_group_label": "SIB Dose-Escalation radiotherapy", 
            "intervention_name": "SIB Dose-Escalation Radiotherapy", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Quality of Life", 
            "Radiotherapy", 
            "Radiotherapy, dose-escalation"
        ], 
        "lastchanged_date": "October 11, 2013", 
        "location": {
            "contact": {
                "email": "camilla.thellenberg@onkologi.umu.se", 
                "last_name": "Camilla\u00a7 Thellenberg KArlsson, MD, PhD", 
                "phone": "+46 90 785 0000"
            }, 
            "contact_backup": {
                "email": "anders.widmark@onkologi.umu.se", 
                "last_name": "Anders Widmark, Professor", 
                "phone": "+46 90 785 00 00"
            }, 
            "facility": {
                "address": {
                    "city": "Ume\u00e5", 
                    "country": "Sweden", 
                    "zip": "90185"
                }, 
                "name": "Ume\u00e5 University, Cancercenter"
            }, 
            "investigator": {
                "last_name": "Camilla Thellenberg Karlsson, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of High Risk Prostatae Cancer Treated With Dose-escalated Simultaneous Integrated Boost to Prostate and Lymph Node GTV", 
        "overall_contact": {
            "email": "camilla.thellenberg@onkologi.umu.se", 
            "last_name": "Camilla Thellenberg Karlsson, MD, PhD", 
            "phone": "+46 90 785 0000"
        }, 
        "overall_contact_backup": {
            "email": "anders.widmark@onkologi.umu.se", 
            "last_name": "Anders Widmark, Professor", 
            "phone": "+46 90 +785 0000"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Sweden: Regional Ethical Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PSA progression defined according to American Society for Therapeutic Radiology and Oncology (ASTRO) Phoenix definition: nadir PSA + 2 ng/mL (on three consecutive measurements with at least one month between each)", 
            "measure": "PSA progression free survival", 
            "safety_issue": "No", 
            "time_frame": "36 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01962324"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ume\u00e5 University", 
            "investigator_full_name": "Camilla Thellenberg Karlsson", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Questionnaires distributed to patients at these time intervals", 
            "measure": "Quality of Life", 
            "safety_issue": "Yes", 
            "time_frame": "0,6,12,36,60 months"
        }, 
        "source": "Ume\u00e5 University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ume\u00e5 University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}